Log in

NASDAQ:TBPH - Theravance Biopharma Stock Price, Forecast & News

$21.09
+0.10 (+0.48 %)
(As of 12/8/2019 03:25 AM ET)
Today's Range
$20.64
Now: $21.09
$21.21
50-Day Range
$15.99
MA: $18.12
$21.76
52-Week Range
$15.18
Now: $21.09
$29.45
Volume212,549 shs
Average Volume254,020 shs
Market Capitalization$1.20 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.81
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TBPH
Previous SymbolNASDAQ:TBPHV
CUSIPN/A
Phone650-808-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$60.37 million
Book Value($0.93) per share

Profitability

Net Income$-215,520,000.00
Net Margins-370.54%

Miscellaneous

Employees363
Market Cap$1.20 billion
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive TBPH News and Ratings via Email

Sign-up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter.


Theravance Biopharma (NASDAQ:TBPH) Frequently Asked Questions

What is Theravance Biopharma's stock symbol?

Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."

How were Theravance Biopharma's earnings last quarter?

Theravance Biopharma Inc (NASDAQ:TBPH) released its quarterly earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($1.05). The biopharmaceutical company had revenue of $12.43 million for the quarter, compared to the consensus estimate of $13.33 million. View Theravance Biopharma's Earnings History.

When is Theravance Biopharma's next earnings date?

Theravance Biopharma is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Theravance Biopharma.

What price target have analysts set for TBPH?

4 equities research analysts have issued 1-year target prices for Theravance Biopharma's shares. Their forecasts range from $18.00 to $55.00. On average, they expect Theravance Biopharma's stock price to reach $34.50 in the next twelve months. This suggests a possible upside of 63.6% from the stock's current price. View Analyst Price Targets for Theravance Biopharma.

What is the consensus analysts' recommendation for Theravance Biopharma?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Theravance Biopharma.

What are Wall Street analysts saying about Theravance Biopharma stock?

Here are some recent quotes from research analysts about Theravance Biopharma stock:
  • 1. Cantor Fitzgerald analysts commented, ". We believe it is a good time to take another look at TBPH given its inexpensive valuation, and ahead of important catalysts this year. We also note that TBPH’s cash and equivalents totaled $517.1MM as of 12/31/18. It appears well-positioned to receive over $1B in milestones and payments, but its market cap is only ~$1.3B. Therefore, we think the peak sales potential of TBPH’s organ-selective Trelegy, are all underappreciated. Our positive investment thesis supports our OW rating and 12-month PT of $55." (4/12/2019)
  • 2. According to Zacks Investment Research, "Theravance reported narrower-than-expected loss in Q4. Also, revenues beat estimates. The company received a huge boost when the FDA approved Yupelri, the first once daily nebulized LAMA option for COPD, in November. Formal launch activities of Yupelri are currently underway. Meanwhile, the agreement to divest its only marketed drug, Vibativ, will enable Theravance to focus solely on the launch efforts of Yupelri. Moreover, its pipeline programs target highly competitive therapeutic areas. The company's collaboration agreements are a consistent source of funds. However, any agreement termination might be a huge setback for the company as was the case in the past. Shares of the company have underperformed the industry so far this year." (3/13/2019)

Has Theravance Biopharma been receiving favorable news coverage?

Media stories about TBPH stock have trended somewhat positive on Sunday, InfoTrie reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Theravance Biopharma earned a news impact score of 2.0 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 8.0 out of 10, meaning that recent media coverage is very likely to have an effect on the stock's share price in the next few days. View News Stories for Theravance Biopharma.

Are investors shorting Theravance Biopharma?

Theravance Biopharma saw a increase in short interest in October. As of October 31st, there was short interest totalling 3,400,000 shares, an increase of 11.1% from the September 30th total of 3,060,000 shares. Based on an average trading volume of 239,500 shares, the days-to-cover ratio is currently 14.2 days. Currently, 9.0% of the company's shares are short sold. View Theravance Biopharma's Current Options Chain.

Who are some of Theravance Biopharma's key competitors?

What other stocks do shareholders of Theravance Biopharma own?

Who are Theravance Biopharma's key executives?

Theravance Biopharma's management team includes the folowing people:
  • Mr. Rick E. Winningham, Chairman & CEO (Age 59)
  • Mr. Bradford J. Shafer, Exec. VP, Gen. Counsel & Sec. (Age 59)
  • Dr. Shehnaaz Suliman M.D., M.Phil., M.B.A., Sr. VP of Corp. Devel. & Strategy (Age 46)
  • Dr. Brett K. Haumann, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 49)
  • Mr. Vijay Sabesan, Sr. VP of Technical Operations

Who are Theravance Biopharma's major shareholders?

Theravance Biopharma's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include State Street Corp (1.67%), California Public Employees Retirement System (0.14%), Chicago Equity Partners LLC (0.14%), California State Teachers Retirement System (0.12%), Squarepoint Ops LLC (0.09%) and NJ State Employees Deferred Compensation Plan (0.07%). Company insiders that own Theravance Biopharma stock include Bradford J Shafer, Burton G Malkiel, Donal O'connor, Philip D Worboys, Renee D Gala and Sharathchandra S Hegde. View Institutional Ownership Trends for Theravance Biopharma.

Which major investors are selling Theravance Biopharma stock?

TBPH stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC and Nisa Investment Advisors LLC. Company insiders that have sold Theravance Biopharma company stock in the last year include Donal O'connor and Sharathchandra S Hegde. View Insider Buying and Selling for Theravance Biopharma.

Which major investors are buying Theravance Biopharma stock?

TBPH stock was purchased by a variety of institutional investors in the last quarter, including Chicago Equity Partners LLC, California Public Employees Retirement System, State Street Corp, NJ State Employees Deferred Compensation Plan, Quadrant Capital Group LLC, Simplex Trading LLC, California State Teachers Retirement System and Tower Research Capital LLC TRC. View Insider Buying and Selling for Theravance Biopharma.

How do I buy shares of Theravance Biopharma?

Shares of TBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Theravance Biopharma's stock price today?

One share of TBPH stock can currently be purchased for approximately $21.09.

How big of a company is Theravance Biopharma?

Theravance Biopharma has a market capitalization of $1.20 billion and generates $60.37 million in revenue each year. The biopharmaceutical company earns $-215,520,000.00 in net income (profit) each year or ($3.99) on an earnings per share basis. Theravance Biopharma employs 363 workers across the globe.View Additional Information About Theravance Biopharma.

What is Theravance Biopharma's official website?

The official website for Theravance Biopharma is http://www.theravance.com/.

How can I contact Theravance Biopharma?

Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The biopharmaceutical company can be reached via phone at 650-808-6000 or via email at [email protected]


MarketBeat Community Rating for Theravance Biopharma (NASDAQ TBPH)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  255 (Vote Outperform)
Underperform Votes:  294 (Vote Underperform)
Total Votes:  549
MarketBeat's community ratings are surveys of what our community members think about Theravance Biopharma and other stocks. Vote "Outperform" if you believe TBPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TBPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel